Early detection

is key

LungLife AI is a diagnostic company focused on the early detection of lung cancer from a simple blood draw enhanced by artificial intelligence.

Our purpose
is simple

Featured News

September 28, 2023

Clinical validation study update

LungLife AI, Inc.(the “Company” or “LungLife”) LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, provides an update on the Company’s clinical validation study for its LungLB® test. As stated in the Company’s half-year report on 8 August 2023, LungLife is currently focussed on preparing data from […]
• Read More
August 14, 2023

Director share purchases

LungLife AI, Inc. (the “Company” or “LungLife”)  Director share purchases LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, announces that it has received notification of the following transactions in the Company’s common shares of US $0.0001 each (“Common Shares”) undertaken by directors. On 14 August 2023, […]
• Read More
1 2 3 24
LungLifeAI Logo
LungLife AI licensure/accreditation information posted here.
© 2023 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.
crosschevron-down